NOVOZYMES A/S: Financial statements 2025
CVR: 10007127
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
NOVOZYMES A/S (CVR 10007127) has filed annual accounts for 2025. In 2025, the company reported revenue of EUR 4,157,600,000 and a net result of EUR 583,600,000 compared with EUR 305,800,000 the year before. That is an increase of 8.5% compared with the year before. The profit margin was 14%. Equity in the 2025 report amounted to EUR 10,855,200,000. The solvency ratio was 66.4%. The company had 11,196 employees in the financial year.
- Revenue
- EUR 4,157,600,000
- Gross Profit
- EUR 2,241,500,000
- Profit/Loss
- EUR 583,600,000
- Equity
- EUR 10,855,200,000
- Total Assets
- EUR 16,349,100,000
- Employees
- 11,196
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 4.2B EUR | 2.2B EUR | 583.6M EUR | 10.9B EUR | 11196 |
| 2024 | 3.8B EUR | 1.8B EUR | 305.8M EUR | 11.2B EUR | 10208 |
| 2023 | 17.9B | 9.7B | 3B | 14.4B | 6805 |
| 2022 | 17.6B | 9.6B | 3.7B | 14.2B | 6690 |
| 2021 | 15B | 8.6B | 3.1B | 12.2B | 6240 |
Official annual report
How creditworthy is NOVOZYMES A/S?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
NOVOZYMES A/S has published its interim report for the period January 1, 2025 to September 30, 2025.
NOVOZYMES A/S has published its interim report for the period January 1, 2025 to June 30, 2025.
NOVOZYMES A/S has published its interim report for the period January 1, 2025 to March 31, 2025.
NOVOZYMES A/S has published its annual report for 2024. Revenue came to DKK 3,833,500,000, and the net result was DKK 305,800,000.
As of April 3, 2025, Mikael Barfred has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Lars Bo Køppler has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Heine Dalsgaard has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Heidi Gelt has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Robert Nøddeskov Jensen has joined the board of directors of NOVOZYMES A/S.
As of April 3, 2025, Frederikke Rose Spenner has joined the board of directors of NOVOZYMES A/S.
About NOVOZYMES A/S
NOVOZYMES A/S is a Danish company of the type Aktieselskab based in Bagsværd, founded in 2000. The company is registered under the industry Fremstilling af andre organiske basiskemikalier. The management consists of Ester Baiget Arnau and Rainer Chapour Lehmann. The board consists of Cornelis de Jong (chair), Heine Dalsgaard, Frederikke Rose Spenner and Kasim Kutay. The company is owned by Novo Holdings A/S and BlackRock, Inc.. The company has 3,508 employees (2026). In 2025, the company reported revenue of EUR 4,157,600,000 and a net result of EUR 583,600,000 compared with EUR 305,800,000 the year before. Equity in the 2025 report amounted to EUR 10,855,200,000.